Shares of Westlake Village-based Arcutis Biotherapeutics shot up 13% on May 15, one day the company announced its earnings results for the first quarter that beat analysts' expectations. Arcutis, a biotechnology company specializing in developing drugs for immune dermatological conditions, generated total revenue worth $49.9 million in the first quarter of 2024, up $47 million from the…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
